BioSpace News Archive

The label for the achondroplasia drug, which promotes endochondral bone growth, now covers children under five years of age with the rare genetic disease causing the most common form of dwarfism.

A Discussion with IQVIA’s Michelle Gyzen Sr. Director, Regulatory Affairs and Drug Development Solutions

Uniting thought leaders across the life sciences landscape, JLABS @ NYC rejoices in five years of catalyzing startups.

A first-in-class clinical trial will initiate this quarter to determine if a checkpoint agonist can down-regulate activated T cells to help reduce inflammation and tissue damage in patients with moderate-to-severe ulcerative colitis (UC).

The competitors posted promising survival data for their respective blockbuster PD-1 inhibitors—Keytruda and Opdivo—emphasizing the potential of these therapies in bladder cancer patients.

The Swiss drugmaker gains rights to RVT-3101 in the U.S. and Japan. Telavant was formed in late 2022 by Roivant and Pfizer, which had a 25% stake in the venture and retains rights to the antibody in other countries.

Avidity Biosciences, Inc. announced that on October 20, 2023, the Human Capital Management Committee of Avidity’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 96,200 shares of its common stock and 48,100 restricted stock units to twelve new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan.

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor and scientific conferences.

Johnson & Johnson announced that Ashley McEvoy, Executive Vice President, Worldwide Chairman of MedTech, informed the company on October 20, 2023, that she is stepping down from her position to pursue other opportunities.

Procaps Group, a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced the appointment of one new member to its Board of Directors.